Filtered By:
Drug: Meridia

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 28 results found since Jan 2013.

Metformin associated with better cardiovascular outcomes than other glycaemic therapies
Context A question exists as to whether the outcome of glycaemic treatment of diabetes varies with the agent used; speculation surrounds whether metformin might be preferable to other treatments. Methods Ghotbi and colleagues performed an epidemiological analysis of 8192 obese patients with diabetes at increased cardiovascular risk participating in the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Mortality and a combined cardiovascular outcome of non-fatal myocardial infarction, non-fatal stroke, resuscitation after cardiac arrest or cardiovascular death were compared among those receiving one of the following interv...
Source: Evidence-Based Medicine - May 19, 2014 Category: Internal Medicine Authors: Bloomgarden, Z. T. Tags: Smoking and tobacco, Epidemiologic studies, Drugs: cardiovascular system, Heart failure, Stroke, Hypertension, Diet, Obesity (nutrition), Ischaemic heart disease, Diabetes, Health education, Smoking Therapeutics Source Type: research

A transcriptomic atlas of drug-induced endothelial dysfunction in human endothelial cells
Drug-induced vascular burden is a critical challenge in both pharmaceutical development and clinical setting. In the past two decades, multiple drugs have been withdrawn from the market due to unanticipated adverse vascular complications, such as the increased risk of myocardial infarction and stroke (e.g., sibutramine and valdecoxib), heart valvular disease (e.g., pergolide and dexfenfluramine), and haemorrhagic stroke (e.g., phenylpropanolamine). Furthermore, many cancer drugs, such as anthracyclines, tyrosine kinase inhibitors (TKIs), and proteasome inhibitors, are also well-known to elicit a broad spectrum of vascular dysfunctions [1].
Source: Journal of Molecular and Cellular Cardiology - October 27, 2022 Category: Cytology Authors: Chengyi Tu, Yu Liu, Damon R. Williams, Joseph C. Wu Tags: Letter to the Editor Source Type: research

Maxiloss Weight Advanced Softgels: Recall - Undeclared Drug Ingredient
Product marketed as dietary supplement contains drug ingredient Sibutramine, and may present a significant risk to patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke.
Source: FDA MedWatch - February 25, 2013 Category: American Health Source Type: news

Orlistat reduces weight but its cost-effectiveness remains unclear
This study aimed to evaluate the effectiveness and cost effectiveness of three pharmacological interventions (orlistat, sibutramine and rimonabant) in obese patients in...
Source: Evidence-Based Nursing - March 8, 2013 Category: Nursing Authors: Veerman, L. Tags: Health policy, General practice / family medicine, Drugs: cardiovascular system, Stroke, Obesity (nutrition), Health service research, Health education, Obesity (public health) Primary healthcare Source Type: research

JaDera and Xiyouji Qingzhi Dietary Supplements by Dolphin Intertrade Corp.: Recall - Undeclared Drug Ingredient
Products have been found to contain undeclared Sibutramine, known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias or stroke.
Source: FDA MedWatch - June 28, 2013 Category: American Health Source Type: news

Association of Hypoglycemic Treatment Regimens on Cardiovascular Outcomes in Overweight and Obese Subjects With Type 2 Diabetes: A Substudy of the SCOUT Trial.
CONCLUSIONSIn obese patients with type 2 diabetes and high risk of cardiovascular disease, monotherapy with metformin or diet-only treatment were associated with lower risk of cardiovascular events than treatment with insulin. PMID: 24089540 [PubMed - as supplied by publisher]
Source: Diabetes Care - October 2, 2013 Category: Endocrinology Authors: Ghotbi AA, Køber L, Finer N, James WP, Sharma AM, Caterson I, Coutinho W, Van Gaal LF, Torp-Pedersen C, Andersson C Tags: Diabetes Care Source Type: research

A safe, effective diet pill - the elusive holy grail
Trade in illegal, ineffective drugs flourishes as pharmaceutical industry repeatedly fails to produce successful pillAttempts to invent a safe and effective diet pill have foundered time and again, allowing the internet trade in illegal and ineffective herbal supplements and dangerous drugs, such as DNP, to flourish.A successful diet pill could make billions for the pharmaceutical industry, but efforts to date have ended in disaster, with patients harmed, drugs banned and massive compensation paid out.Fen-phen, an appetite suppressant, was the most spectacular failure. It was withdrawn in the US in 1997 after causing wides...
Source: Guardian Unlimited Science - January 14, 2014 Category: Science Authors: Sarah Boseley Tags: The Guardian Diets and dieting Drugs trade Healthcare industry World news Pharmaceuticals industry & wellbeing Health policy Society Politics UK news Life and style Public services policy Business Science Source Type: news

Dream Body Slimming Capsule: Public Notification - Undeclared Drug Ingredient
Sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke.
Source: FDA MedWatch - January 22, 2014 Category: American Health Source Type: news

Magic Slim: Public Notification - Undeclared Drug Ingredient
Sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke.
Source: FDA MedWatch - January 22, 2014 Category: American Health Source Type: news

Vitaccino Coffee: Public Notification - Undeclared Drug Ingredient
Sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients, and may also present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke.
Source: FDA MedWatch - March 19, 2014 Category: American Health Source Type: news

Bella Vi Brand Products by Pure Edge Nutrition: Recall - Undeclared Drug Ingredients
Sibutramine can increase blood pressure and/or pulse rate in some patients and may present a risk for those with a history of coronary artery disease, congestive heart failure, arrhymias or stroke.
Source: FDA MedWatch - March 26, 2014 Category: American Health Source Type: news

Thinogenics Products by Nature’s Universe: Recall - Undeclared Drug Ingredient
Use of undeclared sibutramine can lead to increased risk of seizures, heart attacks, arrhythmia and stroke.
Source: FDA MedWatch - April 18, 2014 Category: American Health Source Type: news

Public Notification: Lite Fit USA Contains Hidden Drug Ingredient
This FDA warning advises consumers against purchasing the product Lite Fit USA promoted for weight loss. It contains sibutramine, a controlled substance removed from the market in October 2010 for safety reasons. Sibutramine substantially increases blood pressure and/or pulse rate in some patients and may be a risk for people with a history of heart problems or stroke.
Source: NCCAM Featured Content - April 28, 2014 Category: Complementary Medicine Authors: NCCAM Source Type: news

Cardiovascular effects of current and future anti-obesity drugs.
Abstract The prevalence of obesity increases and is associated with increases in co-morbidities e.g. type 2 diabetes, hyperlipidemia, hypertension, obstructive sleep apnea, heart disease, stroke, asthma, several forms of cancer, depression, and may result in reduction of expected remaining lifespan. We have reviewed the adverse effects on the cardiovascular system of anti-obesity drugs now retracted from the market as well as the cardiovascular profile of current drugs and potential pathways which are considered for treatment of obesity. Fenfluramine, and sibutramine were withdrawn due to increased cardiovascular ...
Source: Current Vascular Pharmacology - May 24, 2014 Category: Drugs & Pharmacology Authors: Comerma-Steffensen S, Grann M, Andersen CU, Rungby J, Simonsen U Tags: Curr Vasc Pharmacol Source Type: research

Association between serum bilirubin and cardiovascular disease in an overweight high risk population from the SCOUT trial
Conclusion: Bilirubin was not a risk-factor independent from other traditional cardiovascular risk-factors in our population.
Source: Nutrition, Metabolism, and Cardiovascular Diseases : NMCD - February 18, 2014 Category: Nutrition Authors: M.E. Jørgensen, C. Torp-Pedersen, N. Finer, I. Caterson, W.P.T. James, U.F. Legler, C. Andersson Tags: Liver abnormalities, diabetes and cardiovascular risk Source Type: research